Literature DB >> 23024005

Symptom onset-to-balloon time and mortality in the first seven years after STEMI treated with primary percutaneous coronary intervention.

Daniela Rollando1, Enrico Puggioni, Stefano Robotti, Angelo De Lisi, Maura Ferrari Bravo, Adriana Vardanega, Ivo Pattaro, Federica De Benedetti, Michele Brignole.   

Abstract

OBJECTIVE: To evaluate the consequence of treatment delay of primary percutaneous coronary intervention (PPCI) on long-term survival.
BACKGROUND: Network organisation based on early recognition, shortening prehospital time delays and procedural delays is the cornerstone of optimal clinical results in the acute phase of ST-segment elevation myocardial infarction (STEMI). Nevertheless, the evidence of a relationship between symptom onset-to-balloon time and mortality is weak, and few long-term data are available. SETTING AND MEASURES: In this single-centre observational follow-up study, we evaluated the long-term survival of 790 consecutive STEMI patients (mean age 68 ± 13 years; 73% males) undergoing PPCI ≤ 12 h from symptom onset, or 12-36 h in the case of persistence of symptoms or hemodynamic instability.
RESULTS: The median (IQR) treatment delay, defined as the time from symptom onset to reperfusion, was 180 min (120;310), fairly balanced between patient delay (80 min (40;140)) and system delay (80 min (60-114)). Patients with a treatment delay <180 min displayed lower mortality at 1, 3, 5 and 7 years (12%, 17%, 22% and 26%, respectively) than those with a treatment delay >180 min (15%, 24%, 28% and 37%, respectively). The HR was 0.7 (95% CI 0.5 to 0.9). On univariate and stepwise multiple regression analysis, field triage and transportation (p=0.0001), shorter distance from hospital (p=0.02) and male gender (p=0.02), but not clinical variables, were independent predictors of shorter treatment delay.
CONCLUSIONS: Shorter symptom onset-to-balloon time predicts long-term lower mortality in STEMI patients treated with PPCI. Our findings emphasise the need to minimise any component of treatment delay.

Entities:  

Mesh:

Year:  2012        PMID: 23024005     DOI: 10.1136/heartjnl-2012-302536

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  15 in total

1.  Almanac 2013: acute coronary syndromes.

Authors:  Pascal Meier; Alexandra J Lansky; Andreas Baumbach
Journal:  Wien Klin Wochenschr       Date:  2014-03       Impact factor: 1.704

2.  Is symptom to balloon time a better predictor of outcomes in acute ST-segment elevation myocardial infarction than door to balloon time?

Authors:  Mershed Alsamara; George Degheim; Gunjan Gholkar; Evan Hiner; Marcel Zughaib
Journal:  Am J Cardiovasc Dis       Date:  2018-10-15

3.  Performance of reperfusion therapy and hospital mortality in ST-elevation myocardial infarction patients with non-chest pain complaints.

Authors:  Jae Phil Na; Kyu Chul Shin; Seunghwan Kim; Yoo Seok Park; Sung Phil Chung; In Cheol Park; Joon Min Park; Min Joung Kim
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

4.  The Current Status of Percutaneous Coronary Intervention in Korea: Based on Year 2014 & 2016 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry.

Authors:  Dong Ho Shin; Hyun Jae Kang; Jae Sik Jang; Keon Woong Moon; Young Bin Song; Duk Woo Park; Jang Whan Bae; Juhan Kim; Seung Ho Hur; Byung Ok Kim; Dong Woon Jeon; Donghoon Choi; Kyoo Rok Han
Journal:  Korean Circ J       Date:  2019-06-21       Impact factor: 3.243

5.  Direct Admission of Patients With ST-Segment-Elevation Myocardial Infarction to the Catheterization Laboratory Shortens Pain-to-Balloon and Door-to-Balloon Time Intervals but Only the Pain-to-Balloon Interval Impacts Short- and Long-Term Mortality.

Authors:  Simcha R Meisel; Michael Kleiner-Shochat; Rami Abu-Fanne; Aaron Frimerman; Asaf Danon; Sa'ar Minha; Yaniv Levi; Alex Blatt; Jameel Mohsen; Avraham Shotan; Ariel Roguin
Journal:  J Am Heart Assoc       Date:  2020-12-21       Impact factor: 5.501

6.  Spatial-time analysis of cardiovascular emergency medical requests: enlightening policy and practice.

Authors:  Ali Azimi; Nasser Bagheri; Sayyed Mostafa Mostafavi; Mary Anne Furst; Soheil Hashtarkhani; Fateme Hashemi Amin; Saeid Eslami; Fatemeh Kiani; Reza VafaeiNezhad; Toktam Akbari; Amin Golabpour; Behzad Kiani
Journal:  BMC Public Health       Date:  2021-01-04       Impact factor: 3.295

7.  Changes in demographics, clinical practices and long-term outcomes of patients with ST segment-elevation myocardial infarction who underwent coronary revascularisation in the past two decades: cohort study.

Authors:  Yasuaki Takeji; Hiroki Shiomi; Takeshi Morimoto; Yusuke Yoshikawa; Ryoji Taniguchi; Yukiko Mutsumura-Nakano; Ko Yamamoto; Kyohei Yamaji; Junichi Tazaki; Eri Toda Kato; Hirotoshi Watanabe; Erika Yamamoto; Yugo Yamashita; Masayuki Fuki; Satoru Suwa; Moriaki Inoko; Teruki Takeda; Manabu Shirotani; Natsuhiko Ehara; Katsuhisa Ishii; Tsukasa Inada; Toshihiro Tamura; Tomoya Onodera; Eiji Shinoda; Takashi Yamamoto; Hiroki Watanabe; Hidenori Yaku; Kenji Nakatsuma; Hiroki Sakamoto; Kenji Ando; Yoshiharu Soga; Yutaka Furukawa; Yukihito Sato; Yoshihisa Nakagawa; Kazushige Kadota; Tatsuhiko Komiya; Kenji Minatoya; Takeshi Kimura
Journal:  BMJ Open       Date:  2021-03-31       Impact factor: 2.692

8.  Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI.

Authors:  Ataollah Doost Hosseiny; Soniah Moloi; Jaya Chandrasekhar; Ahmad Farshid
Journal:  Open Heart       Date:  2016-04-15

9.  Racial Difference in Symptom Onset to Door Time in ST Elevation Myocardial Infarction.

Authors:  Oluwaseyi Bolorunduro; Blake Smith; Mason Chumpia; Poojitha Valasareddy; Mark R Heckle; Rami N Khouzam; Guy L Reed; Uzoma N Ibebuogu
Journal:  J Am Heart Assoc       Date:  2016-09-30       Impact factor: 5.501

10.  Cardiac symptom attribution and knowledge of the symptoms of acute myocardial infarction: a systematic review.

Authors:  Benedikt Birnbach; Jens Höpner; Rafael Mikolajczyk
Journal:  BMC Cardiovasc Disord       Date:  2020-10-14       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.